153 related articles for article (PubMed ID: 17609623)
1. Central venous access device infections in children with hemophilia: a comparison of prophylaxis and episodic therapy.
Hacker MR; Page JH; Shapiro AD; Rich-Edwards JW; Manco-Johnson MJ
J Pediatr Hematol Oncol; 2007 Jul; 29(7):458-64. PubMed ID: 17609623
[TBL] [Abstract][Full Text] [Related]
2. Central venous access device-related infections in patients with haemophilia.
Yeoh ZH; Furmedge J; Ekert J; Crameri J; Curtis N; Barnes C
J Paediatr Child Health; 2013 Mar; 49(3):242-5. PubMed ID: 23438133
[TBL] [Abstract][Full Text] [Related]
3. Central venous access devices for paediatric patients with haemophilia: a single-institution experience.
Titapiwatanakun R; Moir C; Pruthi RK; Stavlo PL; Schmidt KA; Rodriguez V
Haemophilia; 2009 Jan; 15(1):168-74. PubMed ID: 19149849
[TBL] [Abstract][Full Text] [Related]
4. Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.
Komvilaisak P; Connolly B; Naqvi A; Blanchette V
Haemophilia; 2006 Dec; 12 Suppl 6():87-93. PubMed ID: 17123400
[TBL] [Abstract][Full Text] [Related]
5. Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia.
Jeng MR; O'Brien M; Wong W; Zoland J; Lea J; Tang N; Glader B
Haemophilia; 2009 Nov; 15(6):1272-80. PubMed ID: 19601989
[TBL] [Abstract][Full Text] [Related]
6. Consensus recommendations for use of central venous access devices in haemophilia.
Ewenstein BM; Valentino LA; Journeycake JM; Tarantino MD; Shapiro AD; Blanchette VS; Hoots WK; Buchanan GR; Manco-Johnson MJ; Rivard GE; Miller KL; Geraghty S; Maahs JA; Stuart R; Dunham T; Navickis RJ
Haemophilia; 2004 Sep; 10(5):629-48. PubMed ID: 15357790
[TBL] [Abstract][Full Text] [Related]
7. Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS).
Langley AR; Stain AM; Chan A; McLimont M; Chait S; Wu J; Poon MC; Card R; Israels SJ; Laferriere N; Klaassen RJ; Rivard GE; Cloutier S; Hawes S; Feldman B; Blanchette V
Haemophilia; 2015 Jul; 21(4):469-76. PubMed ID: 26104147
[TBL] [Abstract][Full Text] [Related]
8. Venous access in haemophilic children: choice and management.
Santagostino E; Mancuso ME
Haemophilia; 2010 Jan; 16 Suppl 1():20-4. PubMed ID: 20059565
[TBL] [Abstract][Full Text] [Related]
9. Complications associated with central venous access device in children with haemophilia: a nationwide multicentre study in Finland.
Vepsäläinen K; Lassila R; Arola M; Lähteenmäki P; Möttönen M; Mäkipernaa A; Riikonen P
Haemophilia; 2015 Nov; 21(6):747-53. PubMed ID: 25832453
[TBL] [Abstract][Full Text] [Related]
10. Central venous access devices in patients with hemophilia.
Valentino LA; Kapoor M
Expert Rev Med Devices; 2005 Nov; 2(6):699-711. PubMed ID: 16293097
[TBL] [Abstract][Full Text] [Related]
11. MRI after removal of central venous access device reveals a high number of asymptomatic thromboses in children with haemophilia.
Ranta S; Kalajoki-Helmiö T; Pouttu J; Mäkipernaa A
Haemophilia; 2012 Jul; 18(4):521-6. PubMed ID: 22176603
[TBL] [Abstract][Full Text] [Related]
12. Central venous access devices in children with hemophilia: an update.
Blanchette VS; Al-Musa A; Stain AM; Ingram J; Fille RM
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S11-4. PubMed ID: 9351530
[TBL] [Abstract][Full Text] [Related]
13. Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study.
Rodriguez V; Mancuso ME; Warad D; Hay CR; DiMichele DM; Valentino L; Kenet G; Kulkarni R
Haemophilia; 2015 Sep; 21(5):e369-74. PubMed ID: 26178581
[TBL] [Abstract][Full Text] [Related]
14. Surveillance of infectious complications associated with central venous access devices in children with haemophilia.
Tarantino MD; Lail A; Donfield SM; Lynn H; Peddle L; Hunsberger S; Shapiro AD
Haemophilia; 2003 Sep; 9(5):588-92. PubMed ID: 14511299
[TBL] [Abstract][Full Text] [Related]
15. Updated analysis: central venous access device infection rates in an expanded cohort of paediatric patients with severe haemophilia receiving prophylactic recombinant tissue plasminogen activator.
McCarthy CE; O'Brien M; Andrews J; Zoland JM; Macasiray E; Wong W; Lo C; Glader B; Tamaresis J; Jeng M
Haemophilia; 2016 Jan; 22(1):81-6. PubMed ID: 26248602
[TBL] [Abstract][Full Text] [Related]
16. Central venous access devices in haemophilia.
Valentino LA; Ewenstein B; Navickis RJ; Wilkes MM
Haemophilia; 2004 Mar; 10(2):134-46. PubMed ID: 14962202
[TBL] [Abstract][Full Text] [Related]
17. Central venous access device associated infections: recommendations for best practice in home infusion therapy.
Gorski LA
Home Healthc Nurse; 2010 Apr; 28(4):221-9. PubMed ID: 20520262
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters.
Mancuso ME; Mannucci PM; Sartori A; Agliardi A; Santagostino E
Br J Haematol; 2008 May; 141(5):689-95. PubMed ID: 18410458
[TBL] [Abstract][Full Text] [Related]
19. Ethanol-lock therapy for the prevention of central venous access device infections in pediatric patients with intestinal failure.
Cober MP; Kovacevich DS; Teitelbaum DH
JPEN J Parenter Enteral Nutr; 2011 Jan; 35(1):67-73. PubMed ID: 20959638
[TBL] [Abstract][Full Text] [Related]
20. Ethanol lock therapy for the treatment of catheter-related infections in haemophilia patients.
Rajpurkar M; Boldt-Macdonald K; McLenon R; Callaghan MU; Chitlur M; Lusher JM; Becker C
Haemophilia; 2009 Nov; 15(6):1267-71. PubMed ID: 19659937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
